BINV BioInvent International AB (publ)
BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for cancer therapy in Sweden, Europe, the United States, and internationally. The company's drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and T-cell lymphoma; BI-1206, an anti-FcyRIIB antibody in Phase 2a trial for the treatment of non-Hodgkin's lymphoma, and solid tumors; BI-1910, an anti-TNFR2 antibody in Phase 1/2a clinical trial to treat solid tumors; BI-1607, an anti-FcyRIIB antibody in Phase 1b/2a clinical trial to treat solid tumors; and BT-001, an anti- cytotoxic T lymphocyte-associated protein-4 (CTLA-4) antibody in Phase 1/2a clinical trial for the treatment of solid tumors. It has a collaboration with Transgene oncolytic virus platform with BioInvent proprietary antibodies; MSD to evaluate BI-1808, BI-1910, BI-1206, BI-1607, and BT-001 in combination with Keytruda; CASI Pharmaceuticals to develop BI-1206 in both hematological and solid cancers; AstraZeneca to evaluate BI-1206 in combination with rituximab and Calquence; and XOMA. BioInvent International AB (publ) was incorporated in 1996 and is based in Lund, Sweden.…
Industry Peers
BiotechnologyKey Statistics
About BioInvent International (STO: BINV)
›
BioInvent International (STO: BINV) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 107 employees.
The shares were at 2.170 SEK on 19 November 2026, down 93.0% over 52 weeks. Its 52-week range is 1.900 SEK to 34.75 SEK: the price is 93.8% below the high and 14.2% above the low.
Its market capitalisation is 142.80M SEK.
BioInvent International reports return on equity of -59.7% and revenue up 225.0% year over year.
It holds more cash than debt, a net cash position of 205.24M SEK. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. The next earnings report is expected on 4 March 2027.